Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest

Apollomics Inc. (NASDAQ:APLM) was the recipient of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 12,471 shares, a decline of 15.2% from the February 12th total of 14,705 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily trading volume, of 5,401 shares, the short-interest ratio is presently 2.3 days. Based on an average daily trading volume, of 5,401 shares, the short-interest ratio is presently 2.3 days. Approximately 1.1% of the company’s shares are sold short.

Apollomics Trading Up 0.2%

Shares of APLM stock opened at $19.55 on Wednesday. Apollomics has a 12 month low of $3.66 and a 12 month high of $42.12. The stock has a 50 day moving average of $19.96 and a 200-day moving average of $17.95.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apollomics in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Apollomics from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Institutional Investors Weigh In On Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new stake in Apollomics Inc. (NASDAQ:APLM) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned about 0.40% of Apollomics as of its most recent filing with the SEC. Institutional investors own 19.13% of the company’s stock.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.